Product Information
NORETHIN-EE 1.5-0.03 MG(21) TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.3427 per EA under NDC 00378727453. Its NADAC has been published 355 times since Nov 6, 2019.
FDA first approved this application on Feb 19, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.03; 1.5 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378727453
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ETHINYL ESTRADIOL; NORETHINDRONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA202770FDA Approved
2/19/2015
TE Code
AB
On Market Since
9/25/2019
Price Statistics
The NADAC for NORETHIN-EE 1.5-0.03 MG(21) TB has been published 355 times since Nov 6, 2019, and over the history we have for it it has declined 44.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3427 per EA |
|---|---|
| All-time high | $0.6816 (Apr 15, 2020) |
| All-time low | $0.3066 (Jul 17, 2024) |
| 52-week high | $0.3923 |
| 52-week low | $0.3344 |
| Median price | $0.5190 |
| Average price | $0.4932 |
| Largest weekly change | +67.3% (Aug 21, 2024) |
| Weeks tracked | 355 |
| Tracking since | Nov 6, 2019 |
1W
N/A
1M
N/A
3M
-3.6%
6M
+2.5%
1Y
-9.0%
3Y
-31.4%
5Y
-35.9%
All
-44.5%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the norethindrone acetate and ethinyl estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone acetate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NORETHIN-EE 1.5-0.03 MG(21) TB?
The current National Average Drug Acquisition Cost (NADAC) for NORETHIN-EE 1.5-0.03 MG(21) TB, manufactured by Mylan Pharmaceuticals Inc., is $0.3427 per EA (NDC 00378727453), effective Aug 19, 2026.
How has the price of NORETHIN-EE 1.5-0.03 MG(21) TB changed over time?
Over the history we have for it, the NADAC for NORETHIN-EE 1.5-0.03 MG(21) TB has declined 44.5%. It has been tracked across 355 weekly CMS publications since Nov 6, 2019.
What are the highest and lowest recorded NADAC prices for NORETHIN-EE 1.5-0.03 MG(21) TB?
Since Nov 6, 2019, the NADAC for NORETHIN-EE 1.5-0.03 MG(21) TB has ranged from a low of $0.3066 (Jul 17, 2024) to a high of $0.6816 (Apr 15, 2020), with a median of $0.5190 per EA.
Are there cheaper alternatives to NORETHIN-EE 1.5-0.03 MG(21) TB?
No other NADAC-published product currently shares the active ingredient and strength of NORETHIN-EE 1.5-0.03 MG(21) TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NORETHIN-EE 1.5-0.03 MG(21) TB?
NORETHIN-EE 1.5-0.03 MG(21) TB (NDC 00378727453) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.